Evidence map›Paper›PMID 40640094›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2025

[Clinical Characteristics, MAML2 Gene Rearrangement and Prognosis 
of Pulmonary Mucoepidermoid Carcinoma].

Jianrong Bai, Meng Yan, Lingchuan Guo, Zhe Lei, Weishuo Liu, Zigui Zou, Jiao Li, Yushuang Zheng

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jianrong BaiDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Meng YanDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Lingchuan GuoDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Zhe LeiDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Weishuo LiuDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Zigui ZouDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Jiao LiDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Yushuang ZhengDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary pulmonary mucoepidermoid carcinoma (PMEC) is an exceedingly rare malignancy originating from bronchial submucosal glands, accounting for <0.2% of lung cancers. Histologically characterized by a triphasic composition of mucinous, epidermoid, and intermediate cells, PMEC is classified into low-grade (favorable prognosis) and high-grade (aggressive behavior) subtypes. This study aimed to investigate the clinicopathological characteristics and prognostic indicators of PMEC.

methodsClinicopathological, radiological, molecular, and survival data from 26 PMEC patients were retrospectively analyzed, including immunohistochemical profiles and MAML2 rearrangement status, supplemented by literature review.

resultsThe cohort comprised 14 males and 12 females (mean age: 55.6 years). Eight patients (30.8%) were smokers, and 19 (73.1%) presented with symptoms. Central tumors predominated (n=19, 73.1%) versus peripheral lesions (n=7, 26.9%). Computed tomography (CT) imaging consistently revealed hypo-to-isodense masses/nodules. Pathologically, 19 cases were low-grade and 7 high-grade. Immunohistochemically, the tumor cells were positive for CK7, P40, P63 and CK5/6, and the Ki-67 index ranged from 2% to 70%. MAML2 rearrangement was detected in 52.4% (11/21) of tested cases. Clinical staging distribution: stage I (n=14), stage II (n=8), stage III (n=3), stage IV (n=1). Treatment modalities: radical surgery alone (n=13), surgery with adjuvant chemotherapy (n=11), chemoradiotherapy (n=1), and conservative management (n=1). With a median follow-up of 57 months, 6 patients (23.1%) died. Prognostic analysis demonstrated: (1) Significantly inferior survival in high-grade versus low-grade groups (P<0.05); (2) Lymph node metastasis, advanced stage, Ki-67>20%, and high-grade histology significantly correlated with reduced overall survival (P<0.05); (3) Lymph node metastasis constituted an independent poor prognostic factor (HR=12.73, 95%CI: 1.22-132.96).

conclusionsPMEC exhibits distinct clinicopathological features, with MAML2 rearrangement present in approximately half of cases. Lymph node metastasis, advanced stage, high Ki-67 proliferation index, and high-grade histology are key determinants of poor prognosis, with lymph node metastasis serving as an independent risk factor.

Indexed as

Carcinoma, MucoepidermoidDNA-Binding ProteinsGene RearrangementLung NeoplasmsTranscription FactorsAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesTrans-ActivatorsDNA-Binding ProteinsMAML2 protein, humanTrans-ActivatorsTranscription FactorsGradeMAML2 gene rearrangementPrognosisPulmonary mucoepidermoid carcinoma

Identifiers

PMID40640094
PMCPMC12257174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.